Literature DB >> 30830381

Investigation of altered urinary metabolomic profiles of invasive ductal carcinoma of breast using targeted and untargeted approaches.

Tushar H More1,2, Ravindra Taware1, Khushman Taunk1, Venkatesh Chanukuppa1,2, Venkateshwarlu Naik1, Anupama Mane3, Srikanth Rapole4.   

Abstract

INTRODUCTION: Invasive ductal carcinoma (IDC) is a type of breast cancer, usually detected in advanced stages due to its asymptomatic nature which ultimately leads to low survival rate. Identification of urinary metabolic adaptations induced by IDC to understand the disease pathophysiology and monitor therapy response would be a helpful approach in clinical settings. Moreover, its non-invasive and cost effective strategy better suited to minimize apprehension among high risk population.
OBJECTIVE: This study aims toward investigating the urinary metabolic alterations of IDC by targeted (LC-MRM/MS) and untargeted (GC-MS) approaches for the better understanding of the disease pathophysiology and monitoring therapy response.
METHODS: Urinary metabolic alterations of IDC subjects (63) and control subjects (63) were explored by targeted (LC-MRM/MS) and untargeted (GC-MS) approaches. IDC specific urinary metabolomics signature was extracted by applying both univariate and multivariate statistical tools.
RESULTS: Statistical analysis identified 39 urinary metabolites with the highest contribution to metabolomic alterations specific to IDC. Out of which, 19 metabolites were identified from targeted LC-MRM/MS analysis, while 20 were identified from the untargeted GC-MS analysis. Receiver operator characteristic (ROC) curve analysis evidenced 6 most discriminatory metabolites from each type of approach that could differentiate between IDC subjects and controls with higher sensitivity and specificity. Furthermore, metabolic pathway analysis depicted several dysregulated pathways in IDC including sugar, amino acid, nucleotide metabolism, TCA cycle etc.
CONCLUSIONS: Overall, this study provides valuable inputs regarding altered urinary metabolites which improved our knowledge on urinary metabolomic alterations induced by IDC. Moreover, this study identified several dysregulated metabolic pathways which offer further insight into the disease pathophysiology.

Entities:  

Keywords:  Breast cancer; GC–MS; Invasive ductal carcinoma; LC-MRM/MS; Metabolomics; Urine

Mesh:

Substances:

Year:  2018        PMID: 30830381     DOI: 10.1007/s11306-018-1405-1

Source DB:  PubMed          Journal:  Metabolomics        ISSN: 1573-3882            Impact factor:   4.290


  52 in total

Review 1.  The case for early detection.

Authors:  Ruth Etzioni; Nicole Urban; Scott Ramsey; Martin McIntosh; Stephen Schwartz; Brian Reid; Jerald Radich; Garnet Anderson; Leland Hartwell
Journal:  Nat Rev Cancer       Date:  2003-04       Impact factor: 60.716

2.  Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation.

Authors:  Mohit Jain; Roland Nilsson; Sonia Sharma; Nikhil Madhusudhan; Toshimori Kitami; Amanda L Souza; Ran Kafri; Marc W Kirschner; Clary B Clish; Vamsi K Mootha
Journal:  Science       Date:  2012-05-25       Impact factor: 47.728

3.  The role of dysregulated glucose metabolism in epithelial ovarian cancer.

Authors:  L D Kellenberger; J E Bruin; J Greenaway; N E Campbell; R A Moorehead; A C Holloway; J Petrik
Journal:  J Oncol       Date:  2010-02-17       Impact factor: 4.375

Review 4.  'Omics Approaches in Breast Cancer Research and Clinical Practice.

Authors:  Priyakshi Kalita-de Croft; Fares Al-Ejeh; Amy E McCart Reed; Jodi M Saunus; Sunil R Lakhani
Journal:  Adv Anat Pathol       Date:  2016-11       Impact factor: 3.875

5.  Immediate effects of breath holding maneuvers onto composition of exhaled breath.

Authors:  Pritam Sukul; Phillip Trefz; Jochen K Schubert; Wolfram Miekisch
Journal:  J Breath Res       Date:  2014-09-04       Impact factor: 3.262

6.  DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma.

Authors:  Brock C Christensen; Ashley A Smith; Shichun Zheng; Devin C Koestler; E Andres Houseman; Carmen J Marsit; Joseph L Wiemels; Heather H Nelson; Margaret R Karagas; Margaret R Wrensch; Karl T Kelsey; John K Wiencke
Journal:  J Natl Cancer Inst       Date:  2010-12-16       Impact factor: 13.506

Review 7.  Discovery of urine biomarkers for bladder cancer via global metabolomics.

Authors:  Hangchuan Shi; Xiang Li; Qingyang Zhang; Hongmei Yang; Xiaoping Zhang
Journal:  Biomarkers       Date:  2016-05-02       Impact factor: 2.658

Review 8.  Dysregulated metabolism contributes to oncogenesis.

Authors:  Matthew D Hirschey; Ralph J DeBerardinis; Anna Mae E Diehl; Janice E Drew; Christian Frezza; Michelle F Green; Lee W Jones; Young H Ko; Anne Le; Michael A Lea; Jason W Locasale; Valter D Longo; Costas A Lyssiotis; Eoin McDonnell; Mahya Mehrmohamadi; Gregory Michelotti; Vinayak Muralidhar; Michael P Murphy; Peter L Pedersen; Brad Poore; Lizzia Raffaghello; Jeffrey C Rathmell; Sharanya Sivanand; Matthew G Vander Heiden; Kathryn E Wellen
Journal:  Semin Cancer Biol       Date:  2015-10-08       Impact factor: 15.707

Review 9.  Regulation of the pentose phosphate pathway in cancer.

Authors:  Peng Jiang; Wenjing Du; Mian Wu
Journal:  Protein Cell       Date:  2014-07-12       Impact factor: 14.870

Review 10.  Diversity of Breast Carcinoma: Histological Subtypes and Clinical Relevance.

Authors:  Jaafar Makki
Journal:  Clin Med Insights Pathol       Date:  2015-12-21
View more
  2 in total

1.  Serum metabolomic alterations in multiple myeloma revealed by targeted and untargeted metabolomics approaches: a pilot study.

Authors:  Venkatesh Chanukuppa; Tushar H More; Khushman Taunk; Ravindra Taware; Tathagata Chatterjee; Sanjeevan Sharma; Srikanth Rapole
Journal:  RSC Adv       Date:  2019-09-18       Impact factor: 4.036

2.  Liquid biopsies and patient-reported outcome measures for integrative monitoring of patients with early-stage breast cancer: a study protocol for the longitudinal observational Prospective Breast Cancer Biobanking (PBCB) study.

Authors:  Håvard Søiland; Emiel A M Janssen; Thomas Helland; Finn Magnus Eliassen; Magnus Hagland; Oddmund Nordgård; Siri Lunde; Tone Hoel Lende; Jørn Vegard Sagen; Kjersti Tjensvoll; Bjørnar Gilje; Kristin Jonsdottir; Einar Gudlaugsson; Kirsten Lode; Kari Britt Hagen; Birgitta Haga Gripsrud; Ragna Lind; Anette Heie; Turid Aas; Marie Austdal; Nina Gran Egeland; Tomm Bernklev; Timothy L Lash; Linn Skartveit; Ann Cathrine Kroksveen; Satu Oltedal; Jan Terje Kvaløy; Ernst A Lien; Linda Sleire; Gunnar Mellgren
Journal:  BMJ Open       Date:  2022-04-29       Impact factor: 3.006

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.